You just read:

Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145) In Patients With Heterozygous Familial Hypercholesterolemia

News provided by

Amgen

Jan 30, 2014, 04:39 EST